Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 15, 2023
Deals
June 15 Quick Takes: Astellas adds protein degraders in Cullgen deal
Plus: Zentalis, Editas are latest to tap investors for follow-on cash and updates from AbbVie, Mersana, Nordic Bioscience, Aldeyra, Theradaptive
BioCentury | May 24, 2021
Product Development
NGM pivots to ophthamology, cancer as NASH failure raises questions about fibrosis endpoint
NGM appears set to move on from NASH after aldafermin missed the primary endpoint in the Phase IIb ALPINE 2/3 trial, but further analyses from the trial will be needed to help explain whether a
BioCentury | Oct 25, 2019
Tools & Techniques
NASH: how non-invasive biomarkers promise to displace biopsies
Long-term, biomarkers will replace biopsies in NASH. Short-term, they’re aiding patient recruitment.
Items per page:
1 - 5 of 5